OnCusp Therapeutics: Funding, Investors & Team (Sep 2026)
OnCusp Therapeutics, founded by Bing Yuan, Eric Slosberg, and Andy Fu, is a biopharmaceutical company that utilizes advanced research assets to create innovative treatments for cancer. They constantly strive to enhance the most crucial stage in the drug development process, recognizing that accelerating the innovation of oncology medications is the most efficient approach to offer assistance and optimism to cancer patients globally.
OnCusp Therapeutics has raised $100M across 1 funding round on record, the most recent a Series A of $100M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OnCusp Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
OnCusp Therapeutics Funding Rounds
OnCusp Therapeutics Founders and Leadership Team
Contact details for the OnCusp Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →OnCusp Therapeutics Funding Compared to Other Biotechnology Startups
OnCusp Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OnCusp Therapeutics in Biotechnology and New York
Companies Similar to OnCusp Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
OnCusp Therapeutics Funding FAQs
What does OnCusp Therapeutics do?
OnCusp Therapeutics, founded by Bing Yuan, Eric Slosberg, and Andy Fu, is a biopharmaceutical company that utilizes advanced research assets to create innovative treatments for cancer. They constantly strive to enhance the most crucial stage in the drug development process, recognizing that accelerating the innovation of oncology medications is the most efficient approach to offer assistance and optimism to cancer patients globally.
How much funding has OnCusp Therapeutics raised?
OnCusp Therapeutics has raised $100M across 1 round on record. The most recent is a Series A of $100M announced in Jan 2024.
When did OnCusp Therapeutics last raise funding?
OnCusp Therapeutics' most recent funding round on record is a Series A of $100M, announced in Jan 2024.
Who founded OnCusp Therapeutics?
FundedIQ lists Eric Slosberg (Founder) at OnCusp Therapeutics.
Where is OnCusp Therapeutics headquartered?
OnCusp Therapeutics is based in New York, United States.
How many employees does OnCusp Therapeutics have?
OnCusp Therapeutics is in the 11-50 employee band.
How does OnCusp Therapeutics' funding compare to other Biotechnology startups?
OnCusp Therapeutics' latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's OnCusp Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OnCusp Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.